Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

Back to Contracts

Diagnostic Tool Development and Program Support

Active

Grant

Response Deadline07/06/2026, 04:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract focuses on the development and enhancement of diagnostic and surveillance tools, such as rapid tests and mobile applications, tailored for deployment in low-resource settings. The objective is to improve the capabilities for detecting and monitoring health conditions in these environments. Alongside the creation of these tools, the contract also emphasizes supporting in-country capacity building to strengthen health programs, ensuring sustainable improvements in public health infrastructure. Issued by the Centers for Disease Control and Prevention under the Department of Health and Human Services, this subcontract aims to leverage expertise in health technology and program support to address global health challenges. The contract falls under NAICS code 541714, which pertains to research and development in biotechnology. The solicitation was posted in early June 2026, with responses due by early July 2026, demonstrating a relatively short timeframe for proposal submission. The work location details and specific points of contact are not provided, indicating a likely focus on multiple or unspecified low-resource regions.

General Info

Develop diagnostic tools and build local capacity for health monitoring in low-resource settings.

Agency

Department Of Health And Human Services → Centers For Disease Control And Prevention - EraView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJun 4

subcontract

Response DeadlineJul 6

Submission deadline

Response Deadline

07/06/2026, 04:00:00 AM UTCin 1 day

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → Centers For Disease Control And Prevention - Era

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → Centers For Disease Control And Prevention - Era

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Develop and refine diagnostic and surveillance tools (e.g., rapid tests, mobile apps) for use in low-resource settings; support in-country capacity building for health programs.

Similar Contracts

Chromosome Conformation and Whole Genome Sequencing - KINGSTON RIThis contract solicitation seeks quotations for chromosome conformation and whole genome sequencing services under solicitation number 1232SA26Q0618, issued as a combined synopsis and request for quotation in accordance with FAR Part 12. The acquisition is exclusively reserved for small business concerns, with a total small business set-aside designation, and is restricted to entities that do not exceed 1,000 employees as defined by the North American Industry Classification System code 541714. All responsible small businesses are eligible to submit a quote, and no separate written solicitation will be issued—this announcement serves as the complete and only solicitation document. The work is to be performed in Kingston, Rhode Island, with the contracting office located in Beltsville, Maryland, under the auspices of the USDA Agricultural Research Service. The solicitation was posted on July 2, 2026, and responses are due by July 10, 2026, at 10:00 PM Eastern Time. All inquiries should be directed to Shane Pope, the primary point of contact, via email at shane.pope@usda.gov or by phone at 970-851-3735. The opportunity is accessible through the SAM.gov platform, and bidders must ensure full compliance with federal commercial item procurement guidelines.

USDA Ars Afm Apd

POSTED

DEADLINE

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3The RAPIID program, specifically Task Area 3, aims to bridge the gap between lab-scale breakthroughs in shelf-stable blood analogs and real-world deployment by advancing the regulatory approval, manufacturing scalability, and field usability of components originally developed under the FSHARP program. These components, designed to replicate the critical functions of whole blood—oxygen delivery, hemostasis, and volume expansion—now require rigorous clinical validation to demonstrate safety and efficacy when used in combination, as well as scalable production processes to ensure consistent, high-volume output. Efforts under this solicitation will focus on pushing these technologies through the regulatory pathway to secure necessary approvals for military and civilian use in austere, pre-hospital environments. The initiative seeks to develop and scale enabling fielding technologies that support the deployment, storage, and administration of these blood analogs outside controlled laboratory settings. This includes not only the components themselves but also the logistical and operational frameworks needed to integrate them into frontline medical workflows. Proposals must address the full spectrum of challenges—from manufacturing robustness and regulatory compliance to usability in extreme conditions—while aligning with the program’s goal of delivering a complete, authorized system capable of saving lives where traditional blood supplies are unavailable. The solicitation, issued by DARPA’s Biological Technologies Office, has a response deadline of July 29, 2026, and is open to all qualified entities, targeting the NAICS code 541714 for research and development in physical, engineering, and life sciences.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA), under the U.S. Department of Health and Human Services, is seeking proposals through Request for Proposal 75A50126R00002 to advance the late-stage clinical development and regulatory approval of 2-PAM autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. The contract also encompasses the procurement of these autoinjectors for inclusion in the Strategic National Stockpile (SNS) and CHEMPACK programs. The solicitation requires offerors to demonstrate the capability to manufacture 600 mg 2-PAM autoinjectors at a Phase 3 clinical level or higher, with full FDA approval readiness. Proposals must include a comprehensive technical approach covering risk mitigation, project management, inventory control, and post-market surveillance, with mandatory compliance with current Good Manufacturing Practices and FDA guidance for emergency use or approved medical products. The contract features a base period of up to 36 months with up to three optional periods extending performance to a total of 10 years, involving a total potential procurement of 2 million adult-dose autoinjectors across four separate firm-fixed-price line items, each for 500,000 units, supported by cost-plus-fixed-fee line items for development and post-market activities. Deliveries are FOB destination to BARDA’s facility in Washington, D.C., with the contractor responsible for product integrity, temperature control (8–25°C), and security—including GPS tracking, tamper-resistant sealing, and TempTale documentation—until formal government acceptance. Evaluation is conducted on a best-value trade-off basis, with mandatory technical and infrastructure criteria serving as disqualifying thresholds, followed by technical approach, past performance, and cost. Offerors must be current in SAM with a valid UEI and CAGE code, and are subject to strict organizational conflict of interest disclosures, key personnel notification requirements, and prohibitions on the use of funds for abortions, needle distribution for illegal drug use, or human embryo research. Proposals must be submitted electronically via the BDR Portal by July 30, 2026, structured in three distinct volumes under strict page limits, with compliance to HHSAR and FAR clauses governing supply chain risk, anti-lobbying, and inspection standards.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is inviting applications for Disease Research and Translational Core Centers under the P30 mechanism, which is clinical trial optional. These centers aim to strengthen existing research institutions with established programs in cystic fibrosis, diabetes, nutrition, obesity, liver, and digestive diseases by fostering multidisciplinary collaboration, improving research rigor and reproducibility, and enhancing cost efficiency. The centers are structured around shared core services that provide access to specialized equipment, technical resources, analytical support, and expert-led training, all tailored to the specific needs of the research community within the institution. They also include a Pilot and Feasibility Grant Program to support new projects and a Scientific Catalyst Program administered through the Administrative Core, which promotes team building, mentoring, workshops, seminars, and visits by expert scientists to stimulate innovation and attract new investigators to the field. The program places strong emphasis on creating a nurturing environment for trainees and early-stage investigators, ensuring that emerging researchers benefit from mentorship and integrated scientific networks. Core services must be operated or overseen by recognized experts and are designed to be shared across center members to maximize impact and efficiency. The Scientific Catalyst Program specifically supports activities that build research capacity, encourage cross-disciplinary partnerships, and align scientific efforts with the center’s focus on chronic diseases. Applications are expected to demonstrate how the proposed infrastructure will enhance existing strengths and expand the institute’s research trajectory. The funding opportunity was posted on July 2, 2026, and inquiries should be directed to the designated NIDDK contact for further details.

National Institutes Of Health

POSTED

DEADLINE

One-Time FPGA Variant Configuration & Integration (SVC-VARIANT)A one-time engineering service contract has been issued to configure or adapt an FPGA module for a specific operational variant, encompassing firmware customization and full integration testing to ensure compatibility and performance under intended operational conditions. The work is classified under NAICS code 541714 and is structured as a subcontract, with the Naval Air Warfare Center Air Division acting as the overseeing entity under the Department of Defense. Performance is required at Saint Inigoes, Maryland, with a ZIP code of 20684, indicating the physical location where the module adaptation and testing must occur. The solicitation was posted on July 1, 2026, and responses are due by July 14, 2026, at 9:00 PM Eastern Time, leaving a two-week window for qualified vendors to submit proposals. No set-aside designation or specific point of contact has been provided, and the contract is accessible via the SAM.gov platform for interested contractors.

Naval Air Warfare Center Air Division

POSTED

DEADLINE